Navigation Links
Amyloid Beta Level in Serum Predicts Risk for Vascular Disease in First-Degree Relatives of Alzheimer's Patients
Date:2/6/2009

People with a family history of Alzheimer’s disease, who have high levels of amyloid beta (A) in the serum, are at increased risk for vascular disease.

Manhasset, NY (Vocus) February 6, 2009 -- People with a family history of Alzheimer’s disease, who have high levels of amyloid beta (A²) in the serum, are at increased risk for vascular disease. These heightened A² levels may predict whether those without symptoms may progress towards dementia in years to come.

Michael Mullan, MD, and his colleagues at the Roskamp Institute in Sarasota, Fl., collaborated with statisticians at the London School of Hygiene and Tropical Medicine to see if elevated levels of A² in the blood in first-degree relatives of Alzheimer’s patients are associated with risk factors for vascular disease. Recent studies have shown that vascular disease is a major risk factor for Alzheimer’s. They recruited 197 local study subjects from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial, which included unaffected family members, as well as 98 community elders in Florida. They studied the association of amyloid beta levels in serum with risk factors for vascular disease, including total cholesterol, LDL, HDL, systolic blood pressure, diastolic blood pressure and serum creatinine. They also looked at medications prescribed for vascular disease or the risk factors associated with vascular disease.

A² in serum is used as a marker to predict A² accumulation in the brain, which is one of the key pathologies of Alzheimer’s. In this study, the scientists found A² levels were significantly higher in first-degree relatives of Alzheimer’s patients, as compared with the elder community controls. The scientists say they suspect this elevation may be “indicative of increased amyloid beta production due to genetic and/or other risk factors.”

“These findings suggest that an increased risk of Alzheimer’s disease associated with family history may be mediated in part through the enrichment of individuals with vascular risk factors and may be reflective of pre-symptomatic Alzheimer’s disease pathology,” Dr. Mullan and his colleagues wrote.

In another stunning finding in the same issue of Molecular Medicine, scientists from Virginia Commonwealth University, Northwestern University, UCSF, UCLA, University of Pennsylvania, and University of North Carolina, identified a genetic signature for a hepatitis C virus-induced liver cancer, and different genetic handprints for cirrhosis caused by hepatitis C. They were able to use these genetic signatures to distinguish between pathological stages of liver cancer and early disease states, suggesting a way to diagnose this hepatocellular carcinoma earlier in the disease process.

Molecular Medicine is published by The Feinstein Institute for Medical Research, part of the North Shore-LIJ Health System. For more information on the study, visit www.molmed.org or contact Veronica J. Davis. Free podcasts from the latest issue of Molecular Medicine are also available on the journal’s web site and in iTunes.

###

Read the full story at http://www.prweb.com/releases/2009/02/prweb1966994.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
2. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
3. MSU study finds high level of medical mistrust among minority women impacts quality of health care
4. Ther-Rx Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level
5. ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level
6. New Web-Based User Self Service & Identity Management Software for Active Directory takes Security, User Convenience to a Whole New Level
7. Mammography utilization in the United States decreases: A state-level look
8. HPV18 DNA levels are not prognostic for precancerous cervical lesions
9. Cleveland Clinic and Mubadala Healthcare Name CEO of Cleveland Clinic Abu Dhabi
10. New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls
11. Children with inflammatory bowel disease have surprisingly high folate levels, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology: